Persistent infection of the gastrointestinal tract of CFW mice with Candida albicans was produced by the oral-intragastric inoculation of 6-day-old infants. Other intraabdominal organs (liver, kidneys, and spleen) were usually free of the organism in survivors at 20 days of age. However, all survivors retained high levels of the organism in the stomach and intestinal tract at 30 days of age. The possible utility of these persisting C. albicans infections of the gastrointestinal tract for the study of the efficacy of short-term antifungal therapy was studied. Drug treatment was initiated for a 2-week period when the survivors were 15 to 19 days old. Some representative antifungal agents in current use (i.e., amphotericin B, 5-fluorocytosine, and miconazole) effected significant reductions in the numbers of C. albicans in homogenates of gastrointestinal organs.
The number of antifungal agents for candidosis and other mycoses is small; most are toxic, and the indications for their use are varied (7) . The lack of suitable animal models for the study of candidosis as it occurs in humans has hampered understanding of the host-pathogen interrelationships in the disease and impeded the development of improved antifungal therapy. Oral-intragastric inoculation of infant mice leads to systemic spread, lethality, or long-term colonization of the gastrointestinal tract (1, 5 Challenge procedure. Six-day-old mice were pooled to assure random distribution and then fasted for 6 to 8 h. C. albicans was grown on Sabouraud dextrose agar (Difco Laboratories, Detroit, Mich.) slants for 24 h at 37°C. Organisms were harvested with sterile nonpyrogenic saline (Travenol Laboratories, Deerfield, Ill.). The animals were challenged by the oral-intragastric route as described by Guentzel and Berry (2) with approximately 108 colony-forming units contained in 0.05 ml. The actual inoculum was determined by dilution plating on Sabouraud dextrose agar. The mice were returned to the mothers without regard for parentage. Approximately 50% of the animals survived the challenge dose. The surviving animals, who retained high levels of C. albicans in the gastrointestinal tract, were used in the experiments on persistence and antifungal therapy.
Enumeration of organisms. Mice were sacrificed by decapitation and dissected under aseptic conditions. Kidneys, spleen, liver, stomach, and the whole intestine were removed in that order and homogenized in volumes of sterile saline ranging from 2 to 5 ml depending on organ size. Dilutions of the homogenates were plated to Sabouraud dextrose agar containing 50 ,ug of chloramphenicol per ml. The numbers of C. albicans were counted after incubation for 48 h at 37°C. Indigenous yeasts were often present in homogenates of the gastrointestinal tract of older animals. However, they did not complicate enumeration of C. albicans because they had a smaller colony size and a colony morphology that was distinctly different from C. albicans CA 30. The plates were generally free of bacterial growth.
Antungal therapy. C. albicans readily persists in the gastrointestinal tract of mice that survive the oralintragastric challenge as infants (1, 5 (Table 2) . With the exception of miconazole, the treatments studied reduced the numbers of animals positive for C. albicans in the stomach and intestine. Statistical analyses were run on data for individual levels of C. albicans in all control and drug-treated animals within each test group to determine whether the effects of the treatments were significant. However, the data for the different treatments were not compared since they represented separate experiments and single-drug dosages. The effects of separate treatments with AMB and miconazole were significant: AMB stomach (P < 0.00075) and intestine (P = 0.0001); miconazole stomach (P = 0.01) and intestine (P < 0.025). Levels of significance comparing control animals with those treated separately with 5-FC or a combination of 5-FC and AMB were respectively: 5-FC stomach (P < 0.05) and intestine (P = 0.055); 5-FC and AMB stomach (P < 0.005) and intestine (P = 0.0025).
DISCUSSION
The results of this investigation suggest that the persistent gastrointestinal infection that occurs in infant mouse survivors of oral-intragastric inoculation with C. albicans provides a potenially useful model for studies of the efficacy of antifungal agents. Harsh compromising treatment of the animals before or after inoculation is not required to establish the persistent infection (Table 1 ). This contrasts with previous failures to establish C. albicans in the gut of adult conventional mice without compromising 
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No. (Table 2 ). The concentrations of antifungals in milligrams per kilogram of body weight used for this study were approximately the same as used for humans over a similar period of treatment. However, the frequencies and route (intraperitoneal) of administration differed from that normally used in humans (intravenous for AMB and miconazole and oral for 5-FC). Intraperitoneal administration was the most practical for all of the drugs in this study due to the small size of the animals. Smaller, more frequent dosages of the drugs, particularly of 5-FC, may have improved the efficacy of the treatments.
C. albicans was essentially cleared from extraintestinal intraabdominal organs (liver, kidneys, and spleen) in survivors of oral-intragastric challenge examined at 20 days of age or later (Table 1) . Therefore, the animals examined in this study do not provide a model for antifungal therapy in disseminated infection. However, treatment of persistently infected animals with certain compromising agents leads to pronounced tissue invasion and dissemination of the organisms from the gastrointestinal tract (3). The use of such animals as models for antifungal therapy in disseminated candidosis is being investigated.
